Brokerage : SK Securities Analyst : Shane Han, RA: Seoyoung Ko Investment Rating : BUY (Maintain) Target Price : KRW 1,300,000 (Upward) Core Momentum : Production capacity expansion at Gumi and Gimcheon plants signaling advancing export contracts amid a global interceptor shortage, paving the way for qualitative earnings growth in 2028-2029 📊 1. [Valuation &…
Brokerage : Daishin Securities Analyst : Jeonghwan Cho, CFA Investment Rating : BUY (Maintain) Target Price : KRW 990,000 (Maintain) Core Momentum : Multi-year earnings visibility anchored by secured Middle East export contracts, driving strong top-line and margin expansion through 2027-2028 despite short-term 2Q26 earnings misses 📊 1. [Valuation & Key Financial Metrics] 🚀 2….
Brokerage : Kiwoom Securities Analyst : Hangyeol Lee Investment Rating : BUY (Maintain) Target Price : KRW 1,350,000 (Maintain) Core Momentum : High order visibility and CapEx expansion across Gumi and Gimcheon plants anchoring long-term growth, with Saudi Arabia and Iraq Cheongung-II deliveries commencing in earnest from next year 1. [Valuation & Key Financial Metrics]…
Brokerage : iM Securities Analyst : Yongjin Byun Investment Rating : Buy (Maintain) Target Price : KRW 1,230,000 (Maintain) Core Momentum : Full-year OPM guidance raised to 8% overcoming 2Q base effects, supported by a KRW 24.6T order backlog, global pipeline expansion, and aggressive CapEx/R&D investments 1. [Valuation & Key Financial Metrics] 2. [Market Opportunities…
Brokerage : Shinhan Securities Analyst : Dong-heon Lee, Jihan Lee Investment Rating : BUY (Maintain) Target Price : KRW 980,000 (Maintain) Core Momentum : Structural defense export demand across the Middle East, Europe, and Asia overcoming 2Q earnings variations, backed by a KRW 24.6T backlog and an upgraded 8% OPM guidance 1. [Valuation & Key…
Brokerage : Eugene Investment & Securities Analyst : Seungyun Yang Investment Rating : BUY (Maintain) Target Price : KRW 1,200,000 (Maintain) Core Momentum : Multi-year earnings and margin expansion driven by Cheongung-II exports, production capacity additions across Gumi and Gimcheon facilities, and projected 40% operating profit CAGR over 2027-2028 1. [Valuation & Key Financial Metrics]…
Brokerage : Yuanta Securities Analyst : Jongmin Baik Investment Rating : BUY (Maintain) Target Price : KRW 1,050,000 (Maintain) Core Momentum : Multi-year earnings visibility through 2028 secured by overlapping Cheongung-II revenues across three Middle Eastern nations, alongside an upgraded 2026E full-year OPM guidance of 8% 📊 1. [Valuation & Key Financial Metrics] 🚀 2….
Brokerage : DS Investment & Securities Analyst : Taeho Kang Investment Rating : BUY (Maintain) Target Price : KRW 1,250,000 (Maintain) Core Momentum : Expanding export revenue mix overcoming short-term 2Q seasonality, with medium-to-long term high growth secured by Iraq Cheongung-II mass-production revenue recognition beginning in 2027 and expanding order pipelines across Southeast Asia and…
![[Research] Alteogen (196170) – Shinhan Securities | Record 3 Out-Licensing Deals in 2026 · Rapid Keytruda SC Rollout · H2 Clinical Pipeline Catalysts / 2026-08-06](https://koreaequitylens.com/wp-content/uploads/2026/08/포맷변환알테오젠.jpg)
Brokerage : Shinhan Securities Analyst : Minyong Eom, Seokhyeon Yoon Investment Rating : BUY (Maintained) Target Price : KRW 480,000 (Upgraded) Core Momentum : First Kosdaq biotech to execute 3 global pharma L/O deals in a single year (KRW 1.8 Trillion combined), paired with Keytruda SC conversion tracking faster than market expectations and extensive H2…
Brokerage : Hana Securities Analyst : Seona Kim (RA: Heekyung Lee) Investment Rating : BUY (Maintained) Target Price : KRW 580,000 (Maintained) Core Momentum : Execution of a USD 365 Million ALT-B4 out-licensing deal validates sustained platform demand, while surging Keytruda Qlex sales drive upward revisions to medium-term revenue forecasts. 📊 1. [Valuation & Key…